Research progress on the risk of type Ⅱ diabetes complicated with severe pulmonary tuberculosis

doi:10.19983/j.issn.2096-8493.20250009

Abstract

Abstract:

Type Ⅱ diabetes and pulmonary tuberculosis belong to consumptive diseases. They exist and influence each other. In recent years, the number of diabetes patients around the world has shown a growing trend, which poses a serious threat to the control of tuberculosis. Diabetes patients often have metabolic disorders, but also prone to malnutrition, their own immune function will be damaged, and these factors make them more prone to tuberculosis. Due to the long course and complex condition of type Ⅱ diabetes complicated with pulmonary tuberculosis, and the particularity of diabetes itself, it is easy to induce infection and the recurrence or aggravation of the primary focus, which makes the disease progress rapidly, the treatment effect is poor, and the drug resistance rate is high, and then develops into severe pulmonary tuberculosis. This article reviewed the epidemic characteristics, occurrence mechanism, susceptibility mechanism, interaction and nursing management of type Ⅱ diabetes and severe pulmonary tuberculosis, so as to provide basis for health management and practice of diabetes complicated with severe pulmonary tuberculosis.

Key words: Diabetes mellitus, type 2, Tuberculosis, pulmonary, Risk factors, Review

CLC Number:

R52
R587.1

Qian Mengni, Lu Nihong, Du Yingrong. Research progress on the risk of type Ⅱ diabetes complicated with severe pulmonary tuberculosis[J]. Journal of Tuberculosis and Lung Disease , 2025, 6(2): 225-233. doi: 10.19983/j.issn.2096-8493.20250009

References 47

[1]	中华人民共和国国务院办公厅. 国务院办公厅关于印发中国防治慢性病中长期规划(2017—2025年)的通知. 国办发〔2017〕12号. 2017-01-22.
[2]	International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation, 2021.
[3]	NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet, 2024, 404(10467): 2077-2093. doi:10.1016/S0140-6736(24)02317-1.
[4]	胡鑫洋, 高静韬. 世界卫生组织《2024年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(6): 500-504. doi:10.19983/j.issn.2096-8493.2024164.
[5]	Tendolkar MS, Tyagi R, Handa A. Review of advances in diagnosis and treatment of pulmonary tuberculosis. Indian J Tuberc, 2021, 68(4):510-515. doi:10.1016/j.ijtb.2021.07.002. pmid: 34752322
[6]	吴国锋, 陶晓东, 张秀军. 重症肺结核患者血糖变异性相关指标表达水平及其对预后不良的预测效能分析. 全科医学临床与教育, 2024, 22(7):604-606. doi:10.13558/j.cnki.issn1672-3686.2024.007.007.
[7]	van Crevel R, Critchley JA. The Interaction of Diabetes and Tuberculosis: Translating Research to Policy and Practice. Trop Med Infect Dis, 2021, 6(1):8. doi:10.3390/tropicalmed6010008.
[8]	Awad SF, Critchley JA, Abu-Raddad LJ. Impact of diabetes mellitus on tuberculosis epidemiology in Indonesia: A mathematical modeling analysis. Tuberculosis (Edinb), 2022, 134:102164. doi:10.1016/j.tube.2022.102164.
[9]	国家卫生健康委员会规划发展与信息化司. 2023年我国卫生健康事业发展统计公报. 中国病毒病杂志, 2024, 14(5):416-424. doi:10.16505/j.2095-0136.2024.0083.
[10]	耿子妹, 王潮虹, 龙嗣博, 等. 重症肺结核患者病原学阳性率及利福平耐药结果分析. 中国防痨杂志, 2024, 46(9):1050-1055. doi:10.19982/j.issn.1000-6621.20240165.
[11]	Pitua I, Raizudheen R, Muyanja M, et al. Diabetes and tuberculosis: a systematic review and meta-analyis of mendelian randomization evidence. Diabetol Metab Syndr, 2025, 17(1):46. doi:10.1186/s13098-025-01615-w.
[12]	汪清雅, 胡代玉, 张婷, 等. 重庆市初治肺结核合并糖尿病患者的耐药情况分析. 重庆医学, 2021, 50(2):304-307, 313. doi:10.3969/j.issn.1671-8348.2021.02.027.
[13]	Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019, 7(4): e448-e460. doi:10.1016/S2214-109X(18)30487-X.
[14]	Wu Q, Liu Y, Ma YB, et al. Incidence and prevalence of pulmonary tuberculosis among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Med, 2022, 54(1): 1657-1666. doi:10.1080/07853890.2022.2085318. pmid: 35703920
[15]	姚叶萍, 曾跃彬, 邓永佳. 肺结核病合并2型糖尿病94例的临床特点分析. 中国感染与化疗杂志, 2021, 21(3):271-274. doi:10.16718/j.1009-7708.2021.03.005.
[16]	Liu Q, You N, Pan H, et al. Glycemic Trajectories and Treatment Outcomes of Patients with Newly Diagnosed Tuberculosis: A Prospective Study in Eastern China. Am J Respir Crit Care Med, 2021, 204(3): 347-356. doi:10.1164/rccm.202007-2634OC.
[17]	吴继周, 游楠楠, 竺丽梅, 等. 肺结核合并糖尿病研究进展. 中国热带医学, 2022, 22(8):712-717. doi:10.13604/j.cnki.46-1064/r.2022.08.04.
[18]	Panda S, Seelan DM, Faisal S, et al. Chronic hyperglycemia drives alterations in macrophage effector function in pulmonary tuberculosis. Eur J Immunol, 2022, 52(10):1595-1609. doi:10.1002/eji.202249839.
[19]	Vance J, Santos A, Sadofsky L, et al. Effect of High Glucose on Human Alveolar Macrophage Phenotype and Phagocytosis of Mycobacteria. Lung, 2019, 197(1):89-94. doi:10.1007/s00408-018-0181-z. pmid: 30474709
[20]	聂永聪, 宁夏丽, 杨鹏彥, 等. 糖尿病合并肺结核的免疫学、炎症机制及诊疗的研究进展. 海南医学, 2022, 33(22):2985-2988. doi:10.3969/j.issn.1003-6350.2022.22.034.
[21]	陈晶晶, 张念志, 薛晓明, 等. 肺结核合并糖尿病诊治的研究进展. 中国民族民间医药, 2023, 32(1):65-68, 73.
[22]	Peng YF. Pulmonary tuberculosis and diabetes mellitus: Epidemiology, pathogenesis and therapeutic management (Review). Med Int (Lond), 2023, 4(1):4. doi:10.3892/mi.2023.128.
[23]	孙立娟, 辛欣. 2型糖尿病患者体液免疫水平变化的临床研究. 中国老年学杂志, 2010, 30(1):4-6. doi:10.3969/j.issn.1005-9202.2010.01.002.
[24]	孙亚娟, 时艳丽. 膳食纤维强化肠内营养在糖尿病合并重症肺结核中的应用. 哈尔滨医药, 2021, 41(6):119-120. doi:10.3969/j.issn.1001-8131.2021.06.060.
[25]	GBD Tuberculosis Collaborators. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis, 2018, 18(3):261-284. doi:10.1016/S1473-3099(17)30703-X. pmid: 29223583
[26]	Balakrishnan S, Vijayan S, Nair S, et al. High diabetes prevalence among tuberculosis cases in Kerala, India. PLoS One, 2012, 7(10):e46502. doi:10.1371/journal.pone.0046502.
[27]	李艳静, 高微微, 常占平, 等. 肺结核合并糖尿病对抗结核药物血药浓度的影响. 中国防痨杂志, 2012, 34(1):23-25.
[28]	Ping PA, Zakaria R, Islam MA, et al. Prevalence and Risk Factors of Latent Tuberculosis Infection (LTBI) in Patients with Type 2 Diabetes Mellitus (T2DM). Int J Environ Res Public Health, 2021, 18(1):305. doi:10.3390/ijerph18010305.
[29]	Alebel A, Wondemagegn AT, Tesema C, et al. Prevalence of diabetes mellitus among tuberculosis patients in Sub-Saharan Africa: a systematic review and meta-analysis of observational studies. BMC Infect Dis, 2019, 19(1):254. doi:10.1186/s12879-019-3892-8. pmid: 30866836
[30]	Elmi OS, Hasan H, Abdullah S, et al. Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR-TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia. Malays J Med Sci, 2016, 23(4):17-25. doi:10.21315/mjms2016.23.4.3.
[31]	Mohd Shariff N, Shah SA, Kamaludin F. Predictors of death among drug-resistant tuberculosis patients in Kuala Lumpur, Malaysia: A retrospective cohort study from 2009 to 2013. J Glob Antimicrob Resist, 2016, 6:102-107. doi:10.1016/j.jgar.2016.04.005. pmid: 27530850
[32]	冀小波, 毛敏杰, 徐节坤, 等. 重症肺结核合并真菌感染患者的临床特征及发病危险因素分析. 浙江医学, 2021, 43(18):2013-2016, 2019. doi:10.12056/j.issn.1006-2785.2021.43.18.2020-4285.
[33]	陈珣珣, 赖晓宇, 徐镠粤, 等. 应用γ-干扰素释放试验在2型糖尿病患者中评价结核分枝杆菌潜伏感染的有效性. 现代医院, 2022, 22(6):962-965. doi:10.3969/j.issn.1671-332X.2022.06.044.
[34]	卢彩霞. 2型糖尿病患者内分泌有关指标的紊乱及临床意义研究. 当代医学, 2021, 27(1):180-181. doi:10.3969/j.issn.1009-4393.2021.01.077.
[35]	程耀, 陈洪德, 吴桂辉, 等. 成都市某医院结核重症监护室TB/HIV感染患者死亡相关因素分析. 临床肺科杂志, 2022, 27(11):1746-1750.doi:10.3969/j.issn.1009-6663.2022.11.023.
[36]	王鑫, 魏云霞, 龙雪娟, 等. 重症肺结核死亡的多因素分析及风险模型建立. 临床肺科杂志, 2024, 29(7):1078-1083. doi:10.3969/j.issn.1009-6663.2024.07.018.
[37]	孙搏, 付淑军, 陈桂良, 等. 药物相互作用研究在新药研发和审评决策中的应用. 中国临床药理学与治疗学, 2021, 26(10):1095-1102. doi:10.12092/j.issn.1009-2501.2021.10.001.
[38]	韦柳迎, 文乐敏. 糖尿病与肺结核共病的研究进展. 大众科技, 2023, 25(8):124-127, 164. doi:10.3969/j.issn.1008-1151.2023.08.030.
[39]	van Crevel R, Koesoemadinata R, Hill PC, et al. Clinical management of combined tuberculosis and diabetes. Int J Tuberc Lung Dis, 2018, 22(12):1404-1410. doi:10.5588/ijtld.18.0340. pmid: 30606312
[40]	程爽爽, 李鸿杰, 岳杰. 血糖控制对肺结核合并糖尿病患者治疗及预后的影响分析. 内蒙古医科大学学报, 2024, 46(3):281-284. doi:10.16343/j.cnki.issn.2095-512x.2024.03.015.
[41]	王辉. 强化血糖控制治疗肺结核合并糖尿病患者的临床分析. 中国医药指南, 2022, 20(22):84-87. doi:10.15912/j.cnki.gocm.2022.22.009.
[42]	赖金梅, 马燕芳, 罗兰裕. 胰岛素联合HRZE方案治疗肺结核合并糖尿病患者的临床效果分析. 糖尿病新世界, 2023, 26(7):95-98, 131. doi:10.16658/j.cnki.1672-4062.2023.07.095.
[43]	Shi L, Gao J, Gao M, et al. Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study. Infect Dis Ther, 2021, 10(1):457-470. doi:10.1007/s40121-021-00396-9. pmid: 33515206
[44]	Lin Y, Harries AD, Kumar AMV, et al. Tackling diabetes mellitus and tuberculosis: a new Union guide on the management of diabetes-tuberculosis. Int J Tuberc Lung Dis, 2019, 23(7):771-772. doi:10.5588/ijtld.19.0119. pmid: 31439106
[45]	游楠楠, 陆伟, 竺丽梅, 等. 糖尿病及血糖状况对结核病患者治疗转归的影响. 中华疾病控制杂志, 2020, 24(1):90-96. doi:10.16462/j.cnki.zhjbkz.2020.01.018.
[46]	王海丽. 强化血糖控制治疗肺结核合并糖尿病患者的效果及可行性分析. 糖尿病新世界, 2024, 27(9):77-79, 83. doi:10.16658/j.cnki.1672-4062.2024.09.077.
[47]	赵洁, 张艳. 护理干预对糖尿病患者合并肺结核康复效果影响分析. 糖尿病新世界, 2024, 27(3):109-112. doi:10.16658/j.cnki.1672-4062.2024.03.109.